ARV-806
Phase 1/2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
KRAS G12D Mutation
Conditions
KRAS G12D Mutation, Advanced Solid Cancer
Trial Timeline
May 29, 2025 → Apr 2, 2029
NCT ID
NCT07023731About ARV-806
ARV-806 is a phase 1/2 stage product being developed by Arvinas for KRAS G12D Mutation. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07023731. Target conditions include KRAS G12D Mutation, Advanced Solid Cancer.
What happened to similar drugs?
0 of 2 similar drugs in KRAS G12D Mutation were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
9
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07023731 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in KRAS G12D Mutation